`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`COALITION FOR AFFORDABLE DRUGS VIII LLC, Petitioner
`
`v.
`
`TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
`Patent Owner, based on Electronic Records of PTO
`U.S. Patent 7,932,268 to Rader
`Filing Date: June 21, 2007
`Issue Date: April 26, 2011
`TITLE: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED
`WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING
`SIDE EFFECTS
`_____________________
`
`Inter Partes Review No.: IPR2015-01836
`
`
`
`PETITIONER’S OPPPOSITION TO PATENT OWNER’S
`
`MOTION TO EXCLUDE EVIDENCE
`
`
`
`
`
`
`
`
`
`
`
`Petitioner, Coalition For Affordable Drugs VIII, LLC opposes Patent Owner
`
`The Trustees of the University of Pennsylvania motion to exclude Exhibits 1024,
`
`1025, and 1050-1056 submitted by Petitioner.
`
`
`
`A. Exhibits 1024 and 1025
`
`Patent Owner argues
`
`that Exhibits 1024 and 1025 has not been
`
`authenticated. In particular, Patent Owner argues that “Petitioner has failed to
`
`provide any witness testimony whatsoever regarding the websites from where it
`
`allegedly obtained Exhibits 1024 and 1025, let alone any testimony from a witness
`
`with personal knowledge that the printouts themselves are authentic.”
`
`Patent Owner fails to address the fact that Petitioner submitted the
`
`Declaration of Jeffrey Marx, an attorney and member in good standing of the Bars
`
`of the State of Illinois (2005) and the State of Wisconsin (2005). Exh. 1034. In
`
`that declaration, Mr. Marx authenticated both Exhibits 1024 and 1025. Contrary to
`
`Patent Owner’s assertions (“it appears that Petitioner would contend that Exhibits
`
`1024 and 1025 are webpage printouts. But the Petition makes no attempt to
`
`establish the province of these exhibits”), Mr. Marx provided in his declaration the
`
`website address at which both of these documents could be found. In its motion,
`
`Patent Owner completely ignores the contents of Mr. Marx’s declaration.
`
`1
`
`
`
`
`
`Patent Owner seemingly argues that the information within the documents
`
`has not been authenticated. In this regard, Patent Owner argued, “Petitioner cites
`
`these exhibits on page 4 of the Petition, to support its allegation regarding the
`
`purported price of JUXTAPID.” Patent Owner, however, never contested the
`
`values cited in Petitioner’s exhibits or provided the actual prices cited in these
`
`documents in any of the numerous papers and exhibits filed by the Patent Owner.
`
`And considering Patent Owner is undoubtedly the best source of such information,
`
`it should hardly be heard to complain about the lack of authenticity of information
`
`it controls.
`
`B.
`
`Exhibits 1046-1051
`
`Exhibits 1046-1051 are the FDA labels for a number of drugs for the
`
`treatment of hypercholesterolemia. Patent Owner objected that the exhibits were
`
`not authenticated. Petitioner responded by submitting the Declaration of
`
`Christopher Casieri (Exhibit 1057) swearing to the authenticity of the labels and
`
`identifying the exact address on the FDA website at which each label could be
`
`located.
`
`Patent Owner seemingly concedes these facts but maintains that the labels
`
`have not been authenticated. In this regard, Patent Owner merely states that
`
`offered proofs “are insufficient to authenticate the labels”. Patent Owner fails to
`
`identify what specifically about the Declaration of Christopher Casieri is
`
`2
`
`
`
`
`
`insufficient to authenticity of the documents.
`
` While not necessary for
`
`authentication, the Declaration provides the specific address where the label is
`
`available.
`
`Patent Owner then argues that the labels are not relevant to prove the state of
`
`the art as of March 7, 2005. The dates of availability of these drugs however are
`
`not contested facts. Statins have been around long before 2005. See for example
`
`testimony of Dr. Richard Gregg:
`
`Q Do you know, at the time that BMS discontinued development on
`lomitapide, were statins commercially available?
`A Yes.
`Q Do you know how long statins had been around at that time?
`A Approximately 10 years. (Ex. 1053, Gregg at 35:18-24)
`
`
`See also, Patent Owner’s Exhibit 2019 reporting the so called “CURVES study” in
`
`1998 comparing five statins. As for ezetimibe, Patent Owner’s expert cites to
`
`several pre-2005 articles describing the ezetimibe alone and in combination with
`
`statins. See Ex. 2179 (Earl, J., et al., Ezetimbe, Nature Reviews, Vol. 2, 2003, 97);
`
`Ex. 2175 (Catapano, A.L., Ezetimibe: a selective inhibitor of cholesterol
`
`absorption, European Heart Journal Supplements (2001) 3 (Supplement E), E6-
`
`E10); Ex. 2182 (Gagne, C., et al., Efficacy and Safety of Ezetimibe
`
`Coadministered With Atorvastatin or Simvastatin in Patients with Homozygous
`
`Familial Hypercholesterolemia, Circulation, 2002; 105:2469-2475).
`
`
`
`Accordingly, the labels are both authenticated and relevant.
`
`3
`
`
`
`
`
`C. Exhibit 1052 (Kimball Deposition Transcript)
`
`Patent Owner filed Exhibit 2304 on August 10, 2016, which is reportedly the
`
`same as Exhibit 1052, for no obvious reason. Exhibits 2304 and 1052 are
`
`transcripts of the deposition of Petitioner's expert. The party taking a deposition
`
`typically files the transcript with the Board. In this instance, the Petitioner's Reply
`
`cites to the transcript as Exhibit 1052. Patent Owner does not cite to either exhibit.
`
`In response to the Patent Owner’s rejection, Petitioner suggested Patent Owner
`
`should delete Exhibit 2304, which they apparently refused.
`
`
`
`Date: November 10, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`Christopher Casieri
`
`
`
`
`
`
`
`4
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
` The undersigned hereby certifies that the foregoing PETITIONER’S
`
`OPPPOSITION TO PATENT OWNER’S MOTION TO EXCLUDE EVIDENCE
`
`list for this proceeding were served on November 10, 2016 by delivering copies via
`
`electronic mail on the following attorneys of record for the Patent Owner.
`
`Lead Counsel
`William G. James
`(Reg. No. 55,931)
`GOODWIN PROCTER LLP
`901 New York Avenue NW
`Washington, DC 20001
`Tel: 202-346-4046
`Fax:202-346-4444
`wjames@goodwinprocter.com
`
`Backup Counsel
`Nicholas K. Mitrokostas
`GOODWIN PROCTER LLP
`Exchange Place
`53 State Street
`Boston, MA 02109-2881
`Tel: 617-570-1913
`Fax:617-523-1231
`nmitrokostas@goodwinprocter.com
`
`Cynthia Lambert Hardman
`(Reg. No. 53,179)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`Tel: 212-459-7295
`Fax:212-355-3333
`chardman@goodwinprocter.com
`
`
`
`Date: November 10, 2016
`
`Respectfully Submitted,
`
`/Gregory J. Gonsalves/
`Dr. Gregory J. Gonsalves (Reg. No. 43,639)
`2216 Beacon Lane
`Falls Church, Virginia 22043
`(571) 419-7252
`gonsalves@gonsalveslawfirm.com
`
`
`
`5